viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals chairman tenders resignation

Paradigm is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.

Paradigm Biopharmaceuticals Ltd - Paradigm Biopharmaceuticals confirms chairman resignation
Paradigm develops therapeutics targeting multiple pathways involved in injury

Paradigm Biopharmaceuticals Ltd (ASX:PAR) chairman Graeme Kaufman has tendered his resignation as a director for personal and health reasons.

Kaufman joined the Paradigm board prior to its IPO and ASX listing and has contributed strongly to Paradigm's development and success, reflected in the company this month moving into the ASX 300.

Thanked for contribution

Chief executive officer Paul Rennie said: “Graeme has overseen the development of PAR since the IPO and I would like to personally thank Graeme for his contribution to Paradigm.”

The Paradigm board has appointed CEO Paul Rennie as its interim chairman.

Clinical and commercial expertise

On June 3, the company added to the clinical and commercial development expertise of its management team through the appointments of Jeannie Joughlin and Michael Imperiale.

The appointments add considerable experience and strengthen the team as the company prepares phase-3 trials in osteoarthritis and mucopolysaccharidosis.

Rennie said at the time: “It is a very exciting time for Paradigm and to add two highly experienced staff members whose diverse skills will complement the current Paradigm team is very pleasing.”

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.42 AUD

Market: ASX
Market Cap: $546.57 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...


Paradigm Biopharma CEO 'buoyed, enthusiastic and proud' as it begins dosing...

Paradigm Biopharmaceuticals Ltd's (ASX:PAR) CEO Paul Rennie speaks to Proactive's Andrew Scott after announcing they've initiated a Phase II clinical trial of subcutaneous injectable Pentosan Polysulphate Sodium (iPPS), in patients with the ultra-rare orphan disease Mucopolysaccharidosis Type 1...

on 18/11/20

2 min read